# Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

> **NCT05243212** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 75 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapse Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CAR-BCMA

## Key facts

- **NCT ID:** NCT05243212
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-19
- **Primary completion:** 2024-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243212, "Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05243212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*